CAPE TOWN, SA / ACCESSWIRE / September 23, 2021 /WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
Newly appointed Chief Innovation Officer of M2Bio Sciences,Dr. Riyad Domingo, will present his inaugural webinar on the future of mental health therapeutics derived from the psychedelic prodrug psilocybin.
Dr. Domingo holds a PhD in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town.
He will provide an overview of the company's innovative work leveraging the power of artificial intelligence and additive manufacturing in the drug discovery and development process.
"We are thrilled to share our upcoming webinar October 1st, 2021 at 3 pm South Africa time. For three years the M2bio science team has focused on the science, research and development of psilocybin therapies. Our time has come to share our vision for what we see as being the next generation for drug discovery for mental health therapeutics derived from the psychedelic prodrug psilocybin.'' - said Jeff Robinson, CEO of M2Bio Sciences.
Welcome to the future of personalized medicine for mental illness.
To attend the webinar please signup here.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.